World Alzheimer’s Month takes place each September, to raise awareness about Alzheimer’s disease and all types of dementia.

Alzheimer’s disease is an irreversible degeneration of the brain that causes disruptions in memory, cognition, personality, and other functions that eventually lead to death from complete brain failure.

Worldwide, at least 55 million people are believed to be living with Alzheimer’s disease or other dementias, and this number is expected to increase in the next years if current population trends continue. This is because increasing age is the most important known risk factor for Alzheimer’s disease.

Memory problems are typically one of the first signs of Alzheimer’s, though initial symptoms may vary from person to person. A decline in other aspects of thinking, such as finding the right words, vision/spatial issues, and impaired reasoning or judgment, may also signal the very early stages of the disease.

There has been significant progress in recent years in developing and testing new treatments, however currently, there is no cure for Alzheimer’s disease.

GCT is proud to be taking an active part throughout the years in the research of new treatments for this devastating disease. Please contact us at to find out more about our CNS portfolio and how we can assist you in conducting a clinical trial.

#GCT_awareness #WorldAlzheimersMonth #AlzheimersDisease #alzheimers #brain #dementia #health #GCT #GlobalClinicalTrials #CRO #clinicalresearch #drugdevelopment #medicine #pharma #clinicaltrials #clinicaltrial #gctrials #research #CNS